CytoSorbents Corporation to Exhibit at the Force Health Protection Conference and ATACCC

MONMOUTH JUNCTION, NJ–(Marketwire – July 26, 2010) –  CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced that it is exhibiting at two leading military healthcare conferences in August. The first is the 13^th Annual Force Health Protection Conference (FHP) at the Phoenix Convention Center in Phoenix, Arizona, where CytoSorbents will exhibit in Booth #507 from August 10-11, 2010 (http://phc.amedd.army.mil/fhpc/). The FHP conference is expected to gather more than 2,000 healthcare medical providers, policymakers and vendors from around the world, focused on the latest research, services and products for disease prevention and treatment, safety and homeland security for both military and public health purposes.

The second is the Advanced Technology Applications for Combat Casualty Care (ATACCC) Conference to be held at the Tradewinds Beach Resort, in St. Pete Beach, Florida. CytoSorbents will be exhibiting from August 16-19, 2010 in Booth #19. ATACCC is the Department of Defenses’ premier scientific meeting that addresses critical advances in trauma medicine and the unique medical needs of the warfighter (https://www.ataccc.org/). At both venues, the Company will be showcasing its blood purification technology with a hands-on demonstration of how the device works, how it is easily administered, and how it could be applied in a number of clinical situations facing critically wounded military personnel.

Dr. Phillip Chan, Chief Executive Officer and President, commented, “Members of our military forces put their lives on the line every day, not only in Iraq and Afghanistan, but all over the world. The injuries they sustain in protecting our freedom include penetrating wound injuries, infection and sepsis, and blast, trauma, crush and burn injuries that are extremely complex and severe. Standard of care therapy remains predominantly supportive, and does not address the cytokine storm and subsequent severe inflammation that can lead to multi-organ failure and death in these patients.” 

Dr. Chan continued, “We believe that our flagship product CytoSorb™, a powerful cytokine removal technology currently in human clinical trials, is the key to changing the current treatment paradigm of ‘supportive care and watchful waiting’ to one of ‘active treatment,’ potentially saving more lives. In addition, blood purification using CytoSorb or other resins under development, may solve many other vexing problems facing the military and the DOD, such as how to treat soldiers or civilians exposed to chemical or biologic warfare. Exhibiting at these major conferences continues our efforts to build funding support for our technologies within the military and the DOD and to expand the number of clinical applications for our products.”

About CytoSorbents and CytoSorb™

CytoSorbents Corporation is a critical care focused therapeutic device company in clinical trials to treat severe sepsis, the end result of “overwhelming infection,” with a novel blood purification device called CytoSorb™. Severe sepsis afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Severe sepsis is typically triggered by bacterial infections like pneumonia, or viral infections like influenza. However, it is the body’s abnormal immune response to the trigger that leads to severe inflammation and the unregulated, massive production of cytokines, often called “cytokine storm,” that then causes multi-organ failure and often death. CytoSorb™ is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped repeatedly through the CytoSorb™ cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial – a multi-center, randomized, controlled clinical trial using CytoSorb™ to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb™ in the European Union and then commence clinical trials in the U.S. for approval. Importantly, cytokine reduction via CytoSorb™ has broad applicability to a number of other critical care diseases where cytokine storm plays a detrimental role, including burn and smoke inhalation injury, trauma, acute respiratory distress syndrome, advanced influenza, acute pancreatitis and others. CytoSorb™ is one of a number of different resins designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy during treatment of cancer with high dose regional chemotherapy, drug detoxification and others. Additional information is available for download on the Company’s website: www.cytosorbents.com

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management’s current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company’s medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company’s products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company’s Form 10-K filed with the SEC on April 9, 2010, which is available at http://www.sec.gov.